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a b s t r a c t
EphA2 is activated through phosphorylation on serine 897 (S897) by Akt to promote cancer cell motility
and invasion, independently of stimulation by ephrin, its ligand. Here we show that S897 phosphoryla-
tion of EphA2 strengthens the interaction between EphA2 and Ephexin4, a guanine nucleotide exchange
factor for the small GTPase RhoG. S897A mutation of EphA2 abolished the EphA2/Ephexin4-mediated
RhoG activation, promotion of cell migration, and resistance to anoikis. Our results suggest that S897-
phosphorylated EphA2 recruits Ephexin4 to promote cell migration and anoikis resistance, providing a
molecular link between S897 phosphorylation of EphA2 and tumor progression.
C© 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies. Open access under CC BY-NC-ND license.. Introduction
Eph receptors constitute the largest family of receptor tyrosine
inases. Their ligands, ephrins, are membrane-anchored proteins,
hich are divided into two subclasses: class A and class B ephrins,
nd there are also two classes of Eph receptors, EphA and EphB, based
n homology and binding afﬁnity for class A and class B ephrins.
phrin/Eph receptor signaling pathways have many important func-
ions during development and in tissue homeostasis, and many stud-
es have shown that dysregulation of ephrin/Eph receptor signaling
ontributes to cancer progression [1–3]. Among them, EphA2 is fre-
uently overexpressed in a variety of human cancers, and a number of
tudies have reported that overexpression of EphA2 is associatedwith
n aggressive and metastatic cellular phenotype in different types of
ancer cells. EphA2 is phosphorylated by Akt on S897 downstream
f growth factor receptors and promotes cancer cell migration inde-
endently of ligand ephrin stimulation. Furthermore, S897 phospho-
ylation of EphA2 is correlated with malignant progression of humanAbbreviations: GEF, guanine nucleotide exchange factor; GAP, GTPase-activating
rotein; SAM, sterile-α-motif; poly-HEMA, poly-hydroxyethylmethacrylate.
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ttp://dx.doi.org/10.1016/j.fob.2013.01.002astrocytoma [4]. However, themechanisms underlying the oncogenic
effects of S897-phosphorylated EphA2 remain poorly understood.
It is already well known that members of the Rho family of small
GTPases play pivotal roles in the regulation of cellmorphology,migra-
tion, proliferation, and survival. Among them, RhoG is a key upstream
regulator of another Rho familymemberRac to induce diverse cellular
functions, includingpromotionof cellmigration, neurite outgrowth in
neuronal cells, and stimulation of phagocytosis [5–7]. ELMO is an ef-
fector forRhoG thatmediates activationofRac through the interaction
with Rac GEF Dock180 or Dock4. When RhoG is activated, it binds to
ELMO to induce translocation of the ELMO–Dock180 or ELMO–Dock4
complex from the cytoplasm to the plasmamembrane, leading to ac-
tivation of Rac [7–9]. On the other hand, RhoG binds to PI3K p85α
regulatory subunit and activates the PI3K/Akt signaling pathway to
promote cell proliferation and survival independently of the activa-
tion of Rac [10–12]. RhoG-mediated activation of PI3K and Akt also
leads to suppression of anoikis, a subtype of apoptosis induced by
detachment of adherent cells from the extracellular matrix. Anoikis
contributes to the regulation of tissue homeostasis and development,
and resistance to anoikis has been suggested to be a prerequisite for
cancer cells to metastasize [13].
Eph receptors contain a protein kinase domain and a sterile-α-
motif (SAM) domain in the cytoplasmic region and bind to diverse
signaling effectors that regulate the activities of kinases and small GT-
Pases. Among them, Ephexinwas identiﬁed as a subfamily of Dbl type
Rho GEFs that interacts directly with Eph receptors [14,15]. At leastan Biochemical Societies.Open access under CC BY-NC-ND license.
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ported, andwe recently identiﬁed Ephexin4 as a GEF for the Rho fam-
ily small GTPase RhoG. Ephexin4 interacts with EphA2 and mediates
ephrin-independent promotion of cell migration and suppression of
anoikis through activation of RhoG [16,17]. In this study, we have in-
vestigated the relationship between S897 phosphorylation of EphA2
and Ephexin4-mediated signaling pathway. We show that phospho-
rylationof EphA2onS897byAkt regulates theEphA2–Ephexin4 inter-
action and EphA2-mediated RhoG activation to promote cell migra-
tion. We also provide evidence that S897 phosphorylation of EphA2
is crucial for EphA2-mediated resistance to anoikis.
2. Materials and methods
2.1. Plasmids and antibodies
The expression plasmid pCAG encoding YFP was a generous gift
from Drs. J. Miyazaki (Osaka University, Osaka, Japan) and T. Saito
(Chiba University, Chiba, Japan). Plasmids expressing Myc-tagged
EphA2, Flag-tagged Ephexin4, HA-tagged Akt fused with the Src
myristoylation signal at the N terminus, and Myc-tagged RhoG-
V12 were obtained as described previously [5,16,18,19]. EphA2-SA
(S897A) was constructed by PCR-mediated mutagenesis. The shRNAs
for control luciferase, human Ephexin4, and EphA2 were designed to
target 19 nucleotides and expressed by using an shRNA expression
vector pSilencer-hygro (Ambion) as described previously [16].
The following antibodies were used in this study: a mouse mon-
oclonal antibody against Myc, a rabbit polyclonal antibody against
EphA2 (C-20), anda ratmonoclonal antibodyagainst RhoG (1F3B3E5)
(Santa Cruz Biotechnology); mouse monoclonal antibodies against
Flag (M2) and α-tubulin (Sigma); rabbit polyclonal antibodies against
Akt and phosphor-(Ser/Thr) Akt substrate (Cell Signaling); a mouse
monoclonal antibody against EphA2 (clone D7, Millipore); a rabbit
polyclonal antibody against phospho-EphA2 (Ser-897) (Cell Applica-
tions); secondary antibodies conjugated to horseradish peroxidase
(DAKO). Anti-Ephexin4 antibody was described previously [16].
2.2. Cell culture and transfection
HeLa, MCF-7, and HEK293T cells were grown in DMEM containing
10% FBS, 4mMglutamine, 100 units/mlof penicillin, and 0.1mg/mlof
streptomycin under humidiﬁed air containing 5% CO2 at 37
◦C. Cells
were transfected with the indicated plasmids using LipofectAMINE
Plus (for HEK293T cells, Invitrogen) or LipofectAMINE 2000 (for HeLa
and MCF-7 cells), according to the manufacturer’s instructions. To
examine the involvement of Akt, cells were treatedwith Akt inhibitor
IV (an Akt speciﬁc inhibitor, Calbiochem, 1 μM).
2.3. Transwell cell migration assay
Migration of HeLa or MCF-7 cells was evaluated by Transwell mi-
gration assays as described previously [16]. Relative cell migration
was determined by the number of the YFP-positive migrated cells
normalized to the total number of the YFP-positive cells adhering to
the plate. For each experiment, the number of cells in at least eight
random ﬁelds on the underside of the ﬁlter was counted, and four or
ﬁve independent ﬁlters were analyzed.
2.4. Anoikis assay
Cells were detached from tissue culture plates with 0.01% EDTA
in PBS and cultured in complete medium in 24-well plates that had
been coated with poly-hydroxyethylmethacrylate (poly-HEMA) at a
density of 5 × 104 cells/well. They were then collected and ﬁxed
in 4% paraformaldehyde in PBS for 15 min. After washing once with
PBS, they were incubated with Hoechst 33258 (Molecular Probes) inPBS. Hoechst staining in YFP-positive cells was analyzed with a Leica
DC350F digital camera system equipped with a Nikon Eclipse E800
microscope.
2.5. Measurement of RhoG activity
Measurement of RhoG activity in cellswas performed as described
previously [16]. Densitometry analysis was performed with ImageJ
software, and relative RhoG activity was determined by the amount
of RhoG bound to GST-ELMO-NT (amino acids 1–362) normalized to
the amount of RhoG in cell lysates.
2.6. Immunoﬂuorescence microscopy
Cells on coverslips were ﬁxed with 4% paraformaldehyde in PBS
for 15 min and washed with PBS ﬁve times. Cells were permeabilized
with 0.2% Triton X-100 in PBS for 10 min and incubated with 10%
FBS in PBS for 30 min to block nonspeciﬁc antibody binding. Then
cells were incubated with primary antibodies in PBS for 24 h. After
wash with PBS at once, cells were incubated with secondary antibod-
ies conjugated with Alexa Fluor 488 or 594 in PBS for 1 h, washed
with PBS for 30 min, and mounted in 90% glycerol containing 0.1%
p-phenylenediamine dihydrochloride in PBS. Images were captured
using IM50 software (Leica) and a microscope (Eclipse E800, Nikon)
with a 40 × 0.95 objective (Nikon) and a digital camera (DC350F,
Leica).
3. Results
We previously reported that overexpression of EphA2 induced
ligand-independent promotion of cell migration in breast cancer cell
line MCF-7 and cervical carcinoma HeLa cells through Ephexin4-
mediated RhoG activation [16]. To investigate the relationship be-
tweenEphA2S897phosphorylation and theEphexin4-dependent sig-
naling pathway, we overexpressed wild-type EphA2 (EphA2-WT) or
EphA2 containing S897A substitution (EphA2-SA) in these cell lines
and performed Transwell cell migration assays by using FBS as a
chemoattractant. Overexpression of EphA2-WT promoted cell migra-
tion in both MCF-7 (Fig. 1A) and HeLa cells (Fig. 1B), whereas overex-
pression of EphA2-SA did not. To conﬁrm that overexpressed EphA2-
WT, but not EphA2-SA, was phosphorylated on S897, we used an
antibody against phosphorylated S897 of EphA2 (anti-pS897-EphA2
antibody). Immunoprecipitated EphA2-WT was detected with anti-
pS897-EphA2 antibody, but EphA2-SAwas not (Fig. 1C). These results
suggest that S897phosphorylationof EphA2plays a role in theEphA2/
Ephexin4-mediated cell migration.
EphA2 also mediates ligand-independent suppression of anoikis
through Ephexin4 and RhoG [17]. To examine the role of EphA2
S897 phosphorylation in the EphA2/Ephexin4-mediated suppression
of anoikis, we performed an anoikis assay usingHeLa cells transfected
with EphA2-WT or EphA2-SA. After transfection, HeLa cells were cul-
tured in suspension for 24 h, and apoptotic cell deathwas analyzed by
staining of nuclei with Hoechst 33258. In apoptotic cells, nuclear DNA
condensationwas observed (Fig. 2A). As we observed previously [17],
overexpression of EphA2-WT did not cause a further decrease in the
number of apoptotic cells cultured in suspension compared with un-
transfected cells, because HeLa cells acquire resistance to anoikis and
undergo low levels of apoptosis upon detachment from substratum.
Therefore, we performed knockdown and rescue experiments. Trans-
fection of HeLa cells with EphA2 shRNA (shEphA2), which effectively
reduced the protein level of EphA2 in HeLa cells (Fig. 2B), signiﬁ-
cantly increased the number of apoptotic cells cultured in suspension
for 24 h compared with transfection with control shRNA (shControl).
Because shEphA2 used in this study targets human EphA2 mRNA 3′-
untranslated region [16], we used a plasmid expressing Myc-tagged
EphA2,which contains only the coding region of EphA2. Expression of
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Fig. 1. S897A mutation abolishes ligand-independent promotion of cell migration by
EphA2 in MCF-7 and HeLa cells. (A and B) Motility of MCF-7 (A) or HeLa cells (B)
was evaluated by Transwell cell migration assays. Cells transfected with YFP alone
or together with EphA2-WT or EphA2-SA were plated in the upper chamber of the
ﬁlters, and at 4 h after plating, cells that had migrated to the underside of the ﬁlters
were ﬁxed. Relative cell migration was determined by the number of the YFP-positive
migrated cells normalized to the total number of the YFP-positive attached cells. Data
are presented as themeans ± SEM from four or ﬁve independent experiments (***, P<
0.001; t-test). (C) The cell lysates of HeLa cells transfected with Myc-EphA2-WT or -SA
were immunoprecipitated with ephrinA1-Fc, and bound proteins and total cell lysates
were analyzed by immunoblotting with the indicated antibodies.
Fig. 2. S897Amutation abolishes ligand-independent suppression of anoikis by EphA2
in HeLa cells. (A) At 3 days after transfection, HeLa cells were detached from tissue
culture plates and cultured in suspension for 24 h. Then they were collected, and
apoptotic cell death was analyzed by staining of nuclei with Hoechst 33258. Examples
of scored viable (upper panel) and apoptotic (lower panel) HeLa cells are shown. (B)
Lysates from HeLa cells transiently transfected with control luciferase (shControl) or
EphA2 shRNA (shEphA2) were analyzed by immunoblotting with antibodies against
EphA2 and α-tubulin. (C) Apoptotic cells were scored as a percentage of the total
number of transfected cells, and data are the means ± SEM from four independent
experiments (*, P < 0.05; t-test). In one experiment, at least 100 cells were counted in
randomly selected ﬁelds.
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Fig. 3. S897A mutation abolishes EphA2-induced RhoG activation. Cell lysates from
HeLa cells co-transfectedwithMyc-RhoG andMyc-EphA2-WT or EphA2-SAwere incu-
batedwithGST-ELMO, andboundMyc-RhoG (Pull-down) and total cell lysates (Lysates)
were analyzed with anti-Myc antibody. Relative RhoG activity was determined by the
amount of GTP-bound active Myc-RhoG normalized to the amount of Myc-RhoG in
cell lysates analyzed by ImageJ software, and the data shown are relative to the basal
activity (None). Data are presented as the means ± SEM from three independent
experiments (*, P < 0.05; t-test).phA2-WT completely suppressed the shEphA2-induced promotion
f anoikis, whereas expression of EphA2-SA did not (Fig. 2C). In these
xperiments, we conﬁrmed that there is no signiﬁcant difference in
xpression levels between EphA2-WT and EphA2-SA by immunoblot-
ing (data not shown). These results suggest that phosphorylation of
phA2 on S897 is also important for the EphA2/Ephexin4-mediated
uppression of anoikis.
Ephexin4 mediates EphA2-induced promotion of cell migration
nd resistance to anoikis through activation of RhoG [16,17]. We next
easuredRhoGactivity in cells expressingEphA2-WTorEphA2-SAby
pull-down assaywithGST-fusedN-terminal RhoG-binding region ofELMO, which could speciﬁcally interact with GTP-bound active RhoG
[8,16]. Expression of EphA2-WT in HeLa cells increased the amount of
active RhoG about 6-fold over the basal level. However, expression of
EphA2-SA had little effect on the RhoG activity (Fig. 3). These results
suggest that EphA2-mediated RhoG activation is regulated by S897
phosphorylation of EphA2. We also measured Rac activity in HeLa
cells by the same pull-down assay using GST-fused CRIB domain of
Pak. However, we could not show a signiﬁcant increase in Rac activity
in HeLa cells expressing EphA2-WT compared to that in the control
cells. A possible reason for this result is that EphA2 binds to a Rac-
speciﬁc GAP β-chimaerin in HeLa cells [18], which may inactivate
another pool of Rac. Therefore total Rac activity in whole cells may
not change when EphA2 is overexpressed.
To determine whether S897 phosphorylation of EphA2 affects
the interaction between EphA2 and Ephexin4, HEK293T cells were
co-transfected with Flag-tagged Ephexin4 and Myc-tagged EphA2-
WT or EphA2-SA, and EphA2 was immunoprecipitated from the cell
lysates with recombinant ephrinA1-Fc chimera. Ephexin4 was co-
immunoprecipitated with EphA2-WT. However, S897A mutation re-
duced the interaction (Fig. 4A). In this experiment, immunoprecip-
itated EphA2-WT was detected with an antibody that recognized
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Fig. 4. Phosphorylation of EphA2 on S897 regulates the interaction between EphA2
and Ephexin4. (A–C and E) The cell lysates of HEK293T cells transfected indicated plas-
mids were immunoprecipitated with ephrinA1-Fc, and bound proteins and total cell
lysates were analyzed by immunoblotting with the indicated antibodies (p-Akt-Sub,
an antibody that recognized phosphorylated Akt substrates at Akt consensus phospho-
rylation sequence; myr-Akt, Akt fused with the Src myristoylation signal at the NH2
terminus). (D) The lysates of MCF-7 cells were immunoprecipitated with anti-EphA2
antibody, and bound proteins and total cell lysates were analyzed by immunoblotting
with the indicated antibodies (pS897-EphA2, an antibody against phosphorylated S897
of EphA2).
Fig. 5. Phosphorylation of EphA2 on S897 regulates the subcellular localization of
Ephexin4. (A) MCF-7 cells were transfected with EphA2-WT or EphA2-SA. At 24 h af-
ter transfection, they were ﬁxed and subjected to immunoﬂuorescent staining with
anti-EphA2 and anti-Ephexin4 antibodies. The right panels show the merge of the two
images with Ephexin4 (magenta) and EphA2 (green). (B) MCF-7 cells were transfected
withGFP togetherwith control luciferase shRNA (shControl) or Ephexin4 shRNA (shEp-
hexin4). At 72h after transfection, theywereﬁxed and subjected to immunoﬂuorescent
staining with anti-Ephexin4 antibody. The right panels show the merge of the two im-
ages with Ephexin4 (magenta) and GFP (green). Bars, 20 μm. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)phosphorylated Akt substrates at Akt consensus phosphorylation se-
quence (p-Akt-Sub), but the antibody failed to detect a band on the
EphA2-SA immunoprecipitate. Treatment of the cells with an Akt in-
hibitor also reduced the level of EphA2 phosphorylation and the in-
teraction between Myc-EphA2-WT and Flag-Ephexin4 (Fig. 4B). On
the other hand, co-expression of a constitutively active form of Akt
(HA-myr-Akt, Akt fused with the Src myristoylation signal at the
NH2 terminus [19]) promoted the EphA2–Ephexin4 interaction (Fig.
4C). To examine whether endogenous interaction between EphA2
and Ephexin4 was also regulated by Akt-dependent phosphoryla-
tion of EphA2, MCF-7 cells were treated with the Akt inhibitor, and
the cell lysates were immunoprecipitated with anti-EphA2 antibody.
Immunoblot analysis with anti-Ephexin4 antibody demonstrates a
reduced interaction between endogenous EphA2 and Ephexin4 in
MCF-7 cells in the presence of the Akt inhibitor (Fig. 4D). We used
anti-pS897-EphA2 antibody to show the effect of the Akt inhibitor on
S897 phosphorylation of EphA2. These results suggest that phospho-
rylation of EphA2 on S897 by Akt promotes the interaction between
EphA2 and Ephexin4.
Because activation of RhoG triggers the PI3K/Akt signaling path-
way [10–12],we next examinedwhether activation of RhoG regulates
the EphA2–Ephexin4 interaction. HEK293T cells were co-transfected
with Flag-Ephexin4 and Myc-EphA2-WT together with a constitu-
tively active form of RhoG (Myc-RhoG-V12), and EphA2 was im-
munoprecipitated from the cell lysates with recombinant ephrinA1-
Fc chimera. We found that co-expression of RhoG-V12 increased the
interaction between EphA2 and Ephexin4 (Fig. 4E), suggesting the ex-
istence a positive feedback mechanism of regulating RhoG activity.
To examine whether S897 phosphorylation of EphA2 regulates
the subcellular localization of Ephexin4,MCF-7 cells were transfectedwith EphA2-WT or EphA2-SA, and endogenous Ephexin4 was visual-
ized with anti-Ephexin4 antibody. Consistent with previous reports
[4], EphA2-WT was localized to cell protrusions at the leading edge
in addition to the cell–cell junctions, and it was also observed in the
perinuclear region inMCF-7 cells. Immunoﬂuorescence staining with
anti-Ephexin4 antibody revealed that Ephexin4 was mainly localized
in the cytoplasm but partly co-localized with EphA2-WT at the lead-
ing edge in the cells expressing EphA2-WT (Fig. 5A). However, little
Ephexin4 staining was observed at the cell–cell junctions. On the
other hand, EphA2-SA was localized to the cell–cell junctions and
the perinuclear region, and expression of EphA2-SA had no effect on
the subcellular localization of Ephexin4. We veriﬁed the speciﬁcity of
Ephexin4 staining in MCF-7 cells transfected with control luciferase
shRNA (shControl) or Ephexin4 shRNA (shEphexin4), showing that
anti-Ephexin4 antibody staining was reduced by Ephexin4 knock-
down (Fig. 5B). These results suggest that phosphorylation of EphA2
on S897 regulates EphA2–Ephexin4 interaction in intact cells.
4. Discussion
EphA2 is phosphorylated on S897 by Akt, and this phosphoryla-
tion is required for ligand-independent promotion of cell migration
by EphA2. In addition, S897 phosphorylation of EphA2 is correlated
with malignant progression of human astrocytoma [4]. In this study,
we report a mechanism by which phosphorylation of EphA2 on S897
induces promotion of cell migration and suppression of anoikis in
cancer cells. We previously described the role of Ephexin4 in the
ligand-independent promotion of cell migration and suppression of
anoikis by EphA2. Ephexin4 interactswith EphA2 to induce activation
of RhoG. RhoG binds to its effector ELMO2 and recruits ELMO2 and
its binding partner Dock4, a GEF for the small GTPase Rac, from the
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Uytoplasm to the plasma membrane. The recruitment of the ELMO2–
ock4 complex triggers a local activation of Rac by Dock4, which
an cause the formation of cortactin-rich protrusion, leading to pro-
otion of cell polarization and migration [16]. On the other hand,
phA2/Ephexin4-mediated RhoG activation also promotes resistance
o anoikis in cancer cells through PI3K/Akt signaling pathway [17].
n the present study, we show that S897 phosphorylation of EphA2
y Akt promotes the interaction between EphA2 and Ephexin4 and
he Ephexin4-dependent RhoG activation, leading to promotion of
ell migration and suppression of anoikis. Thus, our data provide evi-
ence for Ephexin4as amolecular linkbetweenS897phosphorylation
f EphA2 and EphA2-mediated tumor progression.
The cytoplasmic domains of Eph receptors contain several phos-
horylation sites [20,21]. We show here that phosphorylation of
phA2 on S897 regulates the recruitment of Ephexin4. S897 of EphA2
s located in the linker region between the kinase and SAM domains.
e previously demonstrated that EphA2 interacted with Ephexin4
hrough the kinase domain, which was enhanced by deletion of the
-terminal SAM domain and the linker region containing S897 [16].
herefore, the linker region and/or the SAM domain have an in-
ibitory effect on the interaction of EphA2 with Ephexin4, and phos-
horylation of EphA2 on S897 may trigger a conformational change
ithin the cytoplasmic regionandexpose theEphexin4binding site to
romote the interaction with Ephexin4 and the Ephexin4-mediated
hoG activation.
Because activation of RhoG triggers the PI3K/Akt signaling path-
ay [10–12], the EphA2–Ephexin4 interaction might be regulated
ownstreamof RhoG through Akt. There have been some previous re-
orts showing positive feedback regulations of the Rho family GTPase
ctivities. For example,Dia1, in addition to its role as adownstreamef-
ector for RhoA, can bind to the leukemia-associated Rho-GEF (LARG)
nd stimulates its GEF activity on RhoA, and this positive feedback
oop toward RhoA activity is necessary for LPA-stimulated Rho/ROCK
ignaling for tumor cell morphology and invasion [22]. On the other
and, RhoG is a potent activator of the PI3K/Akt signaling pathway
10–12], and we show here that expression of constitutively active
hoG or Akt promotes the interaction between EphA2 and Ephexin4
hrough S897 phosphorylation of EphA2. Based on these ﬁndings,
t is conceivable that activation of RhoG downstream of EphA2 and
phexin4may promote the interaction between EphA2 and Ephexin4
hrough the activation of PI3K and Akt, which in turn activates addi-
ional RhoG, providing a positive feedback mechanism of RhoG acti-
ation by EphA2 and Ephexin4.
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